FOXO4-DRI CAS:2460055-10-9

FOXO4-DRI is investigated for its therapeutic potential in combating aging-related diseases by targeting senescent cells. Senescence, a state of irreversible growth arrest, contributes to age-related tissue dysfunction and chronic diseases. FOXO4-DRI works by disrupting the interaction between FOXO4 and p53, key regulators of senescence, thereby promoting the apoptosis (programmed cell death) of senescent cells. Accumulation of senescent cells is associated with inflammation and tissue degradation in aging organs. FOXO4-DRI has shown promise in preclinical studies by reducing senescent cell burden in various tissues, including kidney, liver, and adipose tissue. By clearing senescent cells, FOXO4-DRI aims to alleviate age-related pathologies and improve overall health span in aging populations. Research indicates that FOXO4-DRI treatment can enhance tissue regeneration and functional recovery in aged animal models, suggesting potential benefits for age-related conditions such as osteoarthritis, cardiovascular diseases, and neurodegenerative disorders. This peptide therapy holds promise for rejuvenation strategies aimed at extending healthy lifespan and delaying the onset of age-related morbidities. Clinical investigations are underway to further evaluate the safety and efficacy of FOXO4-DRI in human subjects, exploring its potential as a therapeutic intervention to mitigate the burden of aging and improve quality of life in elderly populations. Continued research efforts seek to elucidate the full therapeutic spectrum of FOXO4-DRI and optimize its application for aging-related conditions, potentially transforming approaches to healthy aging and age-related disease management.